AOD-9604

AOD-9604 is a synthetic peptide fragment derived from amino acids 176–191 of the C-terminal region of human growth hormone (hGH). Originally developed by Monash University researchers in Australia, AOD-9604 was designed to isolate the lipolytic (fat-burning) activity of hGH without triggering the insulin-like growth factor-1 (IGF-1) axis or the mitogenic effects that drive cell proliferation. The peptide was extensively investigated in clinical trials as a potential anti-obesity agent under the pharmaceutical designation AOD-9604 and eventually obtained GRAS (Generally Recognized as Safe) status from the US FDA for use in food applications — a designation rarely achieved by synthetic peptides.

Mechanism of Action

AOD-9604 exerts its effects primarily through two interrelated pathways:

**Lipolysis stimulation:** The peptide activates β3-adrenergic receptors in adipose tissue, mimicking the fat-mobilizing signal of endogenous growth hormone. Once bound, the receptor-peptide complex activates adenylate cyclase, elevating intracellular cAMP levels. Elevated cAMP activates protein kinase A (PKA), which in turn phosphorylates hormone-sensitive lipase (HSL) and perilipin — the molecular gatekeepers of stored triglycerides inside lipid droplets. Phosphorylated HSL translocates to the lipid droplet surface and begins hydrolyzing triglycerides into free fatty acids (FFAs) and glycerol, which are then exported into circulation for oxidation by metabolically active tissues such as skeletal muscle and liver.

**Lipogenesis inhibition:** Beyond breaking down stored fat, AOD-9604 has demonstrated the capacity to inhibit lipogenic enzymes — particularly fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACC) — reducing the rate at which dietary and hepatic substrates are converted into new triglycerides. This dual action (accelerating fat breakdown while slowing fat storage) is what distinguished AOD-9604 mechanistically from simpler adrenergic agents or GH secretagogues.

Importantly, AOD-9604 does not appear to stimulate IGF-1 release in preclinical models, does not promote glucose intolerance or insulin resistance, and does not appear to cause growth plate stimulation — concerns that limit the long-term clinical use of full-length hGH.

Preclinical Research Summary

Animal models provided the initial body of evidence supporting AOD-9604's metabolic activity:

- **Obesity models:** Obese mice treated with AOD-9604 via subcutaneous injection demonstrated significant reductions in body weight and adipose tissue mass compared to controls. Effects were dose-dependent and most pronounced in visceral fat depots. - **Diet-induced obesity:** In high-fat diet rodent models, AOD-9604 administration attenuated weight gain and improved markers of metabolic dysregulation, including elevated circulating FFAs and triglycerides. - **Lean models:** Notably, AOD-9604 demonstrated selectivity — in lean animal models, it did not produce the same degree of weight loss, suggesting the peptide's action is amplified in the presence of excess adipose tissue and the associated altered adrenergic receptor sensitivity. - **Glucose and insulin:** Unlike full hGH, AOD-9604 did not impair glucose tolerance or elevate fasting insulin in the preclinical studies reviewed, a finding that shaped the subsequent clinical program.

Human Clinical Trials

AOD-9604 progressed through several phases of human clinical investigation, making it one of the most thoroughly clinically studied research peptides in the weight management space:

**Phase I (METAOD001):** Established safety and pharmacokinetics in healthy volunteers. AOD-9604 was well tolerated across a range of subcutaneous doses; peak plasma concentrations occurred approximately 15 minutes post-injection with a half-life consistent with rapid clearance, necessitating once or twice daily dosing. No clinically significant adverse events related to glucose metabolism, IGF-1, or hGH-associated side effects were observed.

**Phase IIa:** Dose-ranging trials in overweight and obese subjects evaluated efficacy signals over 12-week periods. Some trials demonstrated statistically significant reductions in body fat compared to placebo, though results were variable across trial iterations. The trials that used oral formulations showed substantially reduced bioavailability versus subcutaneous routes, shaping the decision to continue development with injectable formats.

**Phase IIb (METAOD006):** A larger, multi-site, placebo-controlled trial in obese patients. While AOD-9604 demonstrated a favorable safety profile and numerical trends toward fat loss, the trials did not achieve the predefined clinical endpoints required for regulatory approval as a pharmaceutical drug. Development as a pharmaceutical anti-obesity agent was subsequently discontinued.

Despite the clinical program's conclusion, the preclinical and early human safety data established AOD-9604 as a well-characterized peptide with a documented safety profile — a factor that has contributed to its continued use as a research compound.

Research Applications

Current research interest in AOD-9604 spans several areas:

**Body composition:** The primary research application remains the investigation of AOD-9604's effects on adipose tissue remodeling, with particular interest in visceral fat — the metabolically active fat depot most strongly associated with metabolic syndrome, insulin resistance, and cardiovascular risk. Researchers examining the mechanisms of fat mobilization use AOD-9604 as a tool compound to selectively stimulate lipolysis without the confounding effects of full-length GH.

**Cartilage and joint health:** Emerging preclinical data suggest AOD-9604 may possess chondroprotective properties. In vitro studies have explored its effects on chondrocyte viability and extracellular matrix synthesis. In vivo models of osteoarthritis have shown preliminary signals of reduced cartilage degradation, prompting investigation of AOD-9604 in combination with other peptides known to support connective tissue repair (such as BPC-157).

**Metabolic syndrome:** Given its apparently IGF-1-independent mechanism, researchers studying the intersection of growth hormone biology and metabolic syndrome continue to use AOD-9604 to dissect the contributions of GH receptor signaling pathways to hepatic lipid metabolism and adipogenesis.

**Combination protocols:** AOD-9604 is frequently co-administered with CJC-1295 (a GHRH analog) in research settings where investigators wish to examine simultaneous GH pulse amplification alongside selective peripheral lipolysis. The theoretical rationale is that CJC-1295 increases GH secretion (which signals systemically) while AOD-9604 acts directly at adipose tissue β3 receptors.

Pharmacokinetics

- **Route:** Subcutaneous injection is the primary research route; oral formulations exist but show significantly lower bioavailability - **Tmax:** Approximately 15 minutes post subcutaneous injection - **Half-life:** Short; plasma clearance occurs within hours, consistent with peptide metabolism via proteolytic degradation - **Stability:** Lyophilized form is stable; reconstituted peptide should be refrigerated and used within a defined window consistent with sterile peptide handling protocols - **Molecular weight:** Approximately 1,817 Da

Safety Profile from Clinical Data

The clinical program produced a safety database that is relatively unusual for peptide research compounds:

- No clinically significant effects on IGF-1 levels observed in human trials - No impairment of glucose tolerance or insulin sensitivity documented across Phase I and IIa - Injection site reactions (minor, transient) were the most commonly reported adverse event - No cardiovascular signals, no effects on hematopoiesis, and no organ toxicity identified in the reviewed trial populations - GRAS designation from US FDA for food use, based on the safety data compiled through the clinical program

This does not constitute a claim of safety for all research uses, and all handling and administration should be conducted under appropriate institutional oversight and in compliance with applicable regulations.

Availability and Forms

AOD-9604 is available through research peptide suppliers in lyophilized (freeze-dried) powder form, typically in vials containing 2mg or 5mg. Reconstitution with bacteriostatic water (BW) is standard practice for subcutaneous administration in research settings. Pricing varies by supplier and batch quantity; the compound has broad availability across major research peptide vendors.

Regulatory Status

AOD-9604 is sold exclusively for laboratory research purposes and is not approved by the FDA, EMA, or any major regulatory authority for human therapeutic use. Researchers who work with AOD-9604 must ensure compliance with all applicable institutional, national, and international regulations governing the procurement, storage, and use of research peptides. This compound is for research use only (RUO).